Latest Conference Articles

A post hoc analysis evaluated the safety, efficacy, and tolerability of IDP-126 gel in Black patients with moderate to severe acne, of which there are limited data and literature describing its outcomes in this patient population.

Renata Block, MMS, PA-C, delves into the important and ever-evolving role of physician assistants in dermatology.

The most common conditions or concerns patients reported having that may influence their selection of a JAK inhibitor included an increased risk of MACE and an age above 65 years.

Re-treatment 12 months after initial hyaluronic acid filler treatment resulted in further infraorbital rejuvenation.

Mast spoke with Dermatology Times about her conference workshop, what she's looking forward to ahead of this week's SDPA conference, and the importance of always maintaining a passion for patients.

When sessions, late-breaking research, and more conclude at SDPA Fall 2023, there is no shortage of things to do in Nashville.

Click here to answer today's poll.

The conference aimed at providing dermatology physician assistants with the latest in the field begins tomorrow in Nashville, Tennessee.

If you weren’t able to attend the 2023 Fall Clinical Dermatology Conference or want to review our latest coverage and interviews, our full recap has you covered.

This study aimed to evaluate the association between the disease burden of psoriasis and the switching of systemic biologic therapies in patients with both psoriasis and psoriatic arthritis.

There is a lot of conversation drumming around the boxed warnings for newer JAK inhibitors, and fact versus fiction was discussed at Fall Clinical.

Susan Taylor, MD, walked Fall Clinical attendees through an in-depth hyperpigmentation session that included melasma and its mimickers.

Kirby presented at both Fall Clinical and the Inflammatory Disease Summit in Las Vegas.

Sandra Lee, MD, and other top acne experts took the stage to debate cases and treatments.

Primary and secondary melanoma prevention factors are necessary to reduce patients’ melanoma risk.

The latest CDC data shows an uptick in syphilis, which can lead to a rare form of alopecia or a presentation of psoriasis.

Catch up on coverage from the third day of the 2023 Fall Clinical Dermatology Conference.

Although still in its early stages, the program showcases the potential value of tangible interactions between dedicated navigators and patients in enhancing support and continuity of care.

Christopher Bunick, MD, PhD, reviews Cabtreo’s recent FDA approval and what the new triple-combination gel means for acne patients.

The pharmacokinetic profile of APG777, characterized by an extended half-life, increased exposure, and reduced clearance compared to lebrikizumab, is promising for patients with IL-13-driven diseases.

The goal of Arron et al’s study was to determine if the 40-GEP test could identify high-risk cSCC patients who would benefit from ART in controlling metastatic disease progression.

The positive outcomes observed in these cases underscore the potential for these products to revolutionize the way dermatology clinicians address visible signs of facial aging.

Shah is presenting alongside a panel of leading experts at Fall Clinical 2023.

Dawn Merritt, DO, and Mark Lebwohl, MD, took the stage to explain the history of CSU, the prevalence of testing and food avoidance, approved treatments, and monitoring treatment improvement for the condition.

Catch up on coverage from the second day of the 2023 Fall Clinical Dermatology Conference.

Francesca Tenconi, president and CEO of Children’s Skin Disease Foundation and Camp Wonder, presented at Fall Clinical 2023 about the challenges of chronic skin conditions in children.

If you weren’t able to attend the 2023 Inflammatory Disease Summit or want to review our latest coverage and interviews, our full recap has you covered.

Kristine Kucera, PA-C, gave an in-depth overview of the JAK-STAT pathway at the 2023 Inflammatory Disease Summit.